Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 12:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 1,228 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: HAV Clear all
Withdrawn No phase listed Observational Accepts healthy volunteers

Prospective Cohort Study: To Provide Evidence & Guidance in Hepatitis C Virus Screening, Comparing the New Birth Cohort Recommendations From the CDC, Versus Classical Traditional Strategies With Established Risk Factors

NCT01813266
View directory record Official record
Conditions
Chronic Hepatitis C Virus Infection
Interventions
Not listed
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced Oct 21, 2026, 12:54 PM EDT
Completed No phase listed Observational

Patient Self-management and Gene Guided Therapy for Chronic Hepatitis C

NCT02006823
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Durham, North Carolina • Rocky Mount, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 15, 2014 · Synced Oct 21, 2026, 12:54 PM EDT
Terminated No phase listed Observational

Breath Test to Assess Hepatic Metabolic Reserve and to Predict Hepatic Decompensation in Cirrhotics

NCT00375011
View directory record Official record
Conditions
Cirrhosis
Interventions
Not listed
Lead sponsor
Meridian Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Oct 21, 2026, 12:54 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Sofosbuvir + Velpatasvir With or Without Ribavirin in Treatment-Naive Adults With Chronic HCV Infection

NCT01858766
View directory record Official record
Conditions
Hepatitis C
Interventions
SOF, VEL, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
379 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
50
States / cities
La Jolla, California • Long Beach, California • Los Angeles, California + 38 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 21, 2026, 12:54 PM EDT
Completed Phase 3 Interventional

PEG-Interferon a-2b + Ribavirin for Treatment of Patients With Chronic Hepatitis C Who Have Previously Failed to Achieve a Sustained Virologic Response Following Interferon Alfa or Interferon a-2b + Ribavirin Therapy

NCT00215865
View directory record Official record
Conditions
Chronic Hepatitis C Virus Infection
Interventions
PEGIntron plus ribavirin
Drug
Lead sponsor
Hepatitis Resource Network
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2005 · Synced Oct 21, 2026, 12:54 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection

NCT03067129
View directory record Official record
Conditions
Hepatitis C Virus (HCV)
Interventions
Glecaprevir/Pibrentasvir Adult Formulation, Glecaprevir + Pibrentasvir Pediatric Formulation
Drug
Lead sponsor
AbbVie
Industry
Eligibility
3 Years to 17 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
15
States / cities
San Francisco, California • Aurora, Colorado • Hartford, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Oct 21, 2026, 12:54 PM EDT
Not listed Not applicable Interventional

The Hepatitis B e-Antigen Negative Disease - Directly Offered Study of Treatment Withdrawal in Patients With e-Antigen Negative Chronic HBV Infection (BeNEG-DO).

NCT02845401
View directory record Official record
Conditions
Chronic Hepatitis B Virus
Interventions
Stop NA therapy
Other
Lead sponsor
California Pacific Medical Center Research Institute
Other
Eligibility
18 Years to 67 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2023 · Synced Oct 21, 2026, 12:54 PM EDT
Completed No phase listed Observational

Social-environmental, Psychosocial, Behavioral, Clinical and Biological Drivers of Disparities in Liver Disease Progression Among Korean American With Chronic Hepatitis B Infection

NCT05117541
View directory record Official record
Conditions
Chronic Viral Hepatitis, Hepatitis B Infection
Interventions
Interview, Biospecimen Collection, Electronic Health Record Review
Other · Procedure
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
365 participants
Timeline
2021 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 21, 2026, 12:54 PM EDT
Completed Phase 4 Interventional Results available

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Enrolled in a Methadone Maintenance Treatment Program.

NCT00087594
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
peginterferon alfa-2a [Pegasys], ribavirin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
7
States / cities
San Francisco, California • Farmington, Connecticut • Honolulu, Hawaii + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2016 · Synced Oct 21, 2026, 12:54 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

VaxTeen Hepatitis B Vaccine Booster Study

NCT00144313
View directory record Official record
Conditions
Hepatitis
Interventions
hepatitis B vaccine
Biological
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
13 Years to 16 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Anchorage, Alaska
Source: ClinicalTrials.gov public record
Updated Sep 21, 2007 · Synced Oct 21, 2026, 12:54 PM EDT
Recruiting Phase 3 Interventional

A Trial of Inebilizumab in Participants With Autoimmune Hepatitis

NCT07598825
View directory record Official record
Conditions
Autoimmune Hepatitis, AIH
Interventions
Inebilizumab, Placebo, Standard of Care
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 74 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
7
States / cities
Little Rock, Arkansas • Rialto, California • Valencia, California + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 21, 2026, 12:54 PM EDT
Completed No phase listed Observational

Epidemiological Study in Children and Adolescents With Chronic Hepatitis B

NCT01163240
View directory record Official record
Conditions
Liver Diseases, Hepatitis, Chronic, Hepatitis, Viral, Human, Hepatitis, Virus Diseases, Digestive System Diseases, Hepatitis B, Chronic, Hepatitis B, DNA Virus Infections
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 18 Years
Enrollment
1,640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
5
States / cities
Aurora, Colorado • Gainesville, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2011 · Synced Oct 21, 2026, 12:54 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Sulfation of Bile Acids as a Biomarker for Hepatobiliary Diseases

NCT01200082
View directory record Official record
Conditions
Hepatobiliary Diseases
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 65 Years
Enrollment
430 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2022
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Oct 21, 2026, 12:54 PM EDT
Completed Phase 4 Interventional Results available

Evaluating Blood Glucose Levels During Infusion With HepaGam B (HBIG) in Post-liver Transplant Patients

NCT00998426
View directory record Official record
Conditions
Hepatitis B
Interventions
glucose monitoring before and after HepaGam B administration, HepaGam B (Hepatitis B Immune Globulin (HBIG))
Procedure · Biological
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 28, 2015 · Synced Oct 21, 2026, 12:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Of Eltrombopag in Healthy Subjects and Volunteers With Mild, Moderate or Severe Hepatic Impairment

NCT00359463
View directory record Official record
Conditions
Purpura, Thrombocytopaenic, Idiopathic
Interventions
eltrombopag
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
2
States / cities
Gainesville, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 21, 2026, 12:54 PM EDT
Completed Phase 2 Interventional Results available

A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to Therapy

NCT00535847
View directory record Official record
Conditions
Hepatitis C
Interventions
Telaprevir, Ribavirin, Pegylated interferon alfa 2a
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 70 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
39
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2014 · Synced Oct 21, 2026, 12:54 PM EDT
Terminated No phase listed Observational Results available

A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection

NCT02292706
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
Sofosbuvir, Ribavirin, LDV/SOF, SOF/VEL, SOF/VEL/VOX, Other SOF-Based Regimen, Ineligible parent treatment
Drug · Other
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
1,609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
77
States / cities
Birmingham, Alabama • La Jolla, California • Long Beach, California + 57 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Oct 21, 2026, 12:54 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

An Arts Intervention for Drug-Using Homeless Youth

NCT00862238
View directory record Official record
Conditions
Drug Use
Interventions
Art Messaging, Health Promotion
Behavioral · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
15 Years to 24 Years
Enrollment
156 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Mar 25, 2013 · Synced Oct 21, 2026, 12:54 PM EDT
Recruiting Phase 3 Interventional

Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)

NCT07428538
View directory record Official record
Conditions
Hepatitis
Interventions
Larsucosterol, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
92
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 21, 2026, 12:54 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children

NCT00197015
View directory record Official record
Conditions
Hepatitis A
Interventions
Havrix®, M-M-R®II, VARIVAX®
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 13 Months
Enrollment
1,474 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2009
U.S. locations
42
States / cities
Cabot, Arkansas • Jonesboro, Arkansas • North Little Rock, Arkansas + 37 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 21, 2026, 12:54 PM EDT
Withdrawn Phase 4 Interventional

Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients

NCT00782301
View directory record Official record
Conditions
Hepatitis B, Human Immunodeficiency Virus, Hepatitis C, Chronic
Interventions
maraviroc, etravirine
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
15
States / cities
Clearwater, Florida • Orlando, Florida • Safety Harbor, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2012 · Synced Oct 21, 2026, 12:54 PM EDT
Withdrawn Phase 4 Interventional

Efficacy of Telbivudine in Blacks/African Americans and Hispanics/Latinos With Compensated Chronic Hepatitis B During 52 Weeks

NCT00862706
View directory record Official record
Conditions
Compensated Chronic Hepatitis B
Interventions
Telbivudine/LDT600A
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
16 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
5
States / cities
Chicago, Illinois • Boston, Massachusetts • Bayside, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2016 · Synced Oct 21, 2026, 12:54 PM EDT
Completed Phase 3 Interventional Results available

The Individualized Management With Pegylated-interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Offering Viral Eradication: A Study of Pegylated-interferon Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C (CHC) Non-genotype 2/3 (IMPROVE)

NCT00483938
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Pegylated-interferon Alfa-2a, Ribavirin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 23, 2017 · Synced Oct 21, 2026, 12:54 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Thousand Asian American Study

NCT02596438
View directory record Official record
Conditions
Hepatitis B
Interventions
Hepatitis B
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
1,076 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2017 · Synced Oct 21, 2026, 12:54 PM EDT